Market Research Industry Reports

Constipation - Pipeline Review, H2 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Constipation - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Constipation - Pipeline Review, H2 2018, provides an overview of the Constipation (Gastrointestinal) pipeline landscape.

Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxatives and proper lifestyle.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Constipation - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 8, 2, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Constipation (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Constipation (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Constipation (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Constipation (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Constipation (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Constipation (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Constipation (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Constipation - Overview
Constipation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Constipation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Constipation - Companies Involved in Therapeutics Development
Allergan Plc
Ardelyx Inc
Braintree Laboratories Inc
Dong-A ST Co Ltd
EA Pharma Co Ltd
Ironwood Pharmaceuticals Inc
Johnson & Johnson
MallInckrodt Plc
NGM Biopharmaceuticals Inc
RaQualia Pharma Inc
Sanwa Kagaku Kenkyusho Co Ltd
SK Biopharmaceuticals Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Synthetic Biologics Inc
Vanda Pharmaceuticals Inc
Yuhan Corp
Zensun (Shanghai) Sci & Tech Co Ltd
Constipation - Drug Profiles
5-BIOP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AJG-555 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLI-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLI-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-6886 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSP-6952 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
J-027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide DR2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lovastatin MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lubiprostone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naronapride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prucalopride succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relenopride hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00000010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SK-1202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenapanor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-12852 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZS-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Constipation - Dormant Projects
Constipation - Discontinued Products
Constipation - Product Development Milestones
Featured News & Press Releases
Jun 03, 2018: New Data on the Cardiovascular Safety of Prucalopride Presented at 2018 Digestive Disease Week Annual Meeting
May 03, 2018: Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS (linaclotide) Patent Litigation
Apr 30, 2018: FDA Responds to Mallinckrodts Supplemental New Drug Application for New Indication for AMITIZA (Lubiprostone)
Mar 05, 2018: U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
Jan 16, 2018: Sun Pharma Announces Settlement of Patent Litigation for Generic Linzess in US
Jan 03, 2018: Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C
Nov 27, 2017: Application for Marketing and Manufacturing Approval of Chronic Constipation Treatment AJG555 Was Filed in Japan
Oct 16, 2017: Allergan to Present New Data on Gastrointestinal Drug Candidate Linaclotide at the World Congress of Gastroenterology at ACG 2017
Oct 16, 2017: Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
Oct 11, 2017: Ardelyxs Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018
Sep 28, 2017: Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review Designation
Sep 11, 2017: Astellas Submits Supplemental New Drug Application for Approval of Additional Indication of "Linaclotide" for Patients with Chronic Constipation in Japan
Jun 27, 2017: Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation
May 12, 2017: Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
May 09, 2017: Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotides Effect on Pain at Digestive Disease Week 2017
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Constipation, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Constipation - Pipeline by Allergan Plc, H2 2018
Constipation - Pipeline by Ardelyx Inc, H2 2018
Constipation - Pipeline by Braintree Laboratories Inc, H2 2018
Constipation - Pipeline by Dong-A ST Co Ltd, H2 2018
Constipation - Pipeline by EA Pharma Co Ltd, H2 2018
Constipation - Pipeline by Ironwood Pharmaceuticals Inc, H2 2018
Constipation - Pipeline by Johnson & Johnson, H2 2018
Constipation - Pipeline by MallInckrodt Plc, H2 2018
Constipation - Pipeline by NGM Biopharmaceuticals Inc, H2 2018
Constipation - Pipeline by RaQualia Pharma Inc, H2 2018
Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2018
Constipation - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2018
Constipation - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2018
Constipation - Pipeline by Synthetic Biologics Inc, H2 2018
Constipation - Pipeline by Vanda Pharmaceuticals Inc, H2 2018
Constipation - Pipeline by Yuhan Corp, H2 2018
Constipation - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2018
Constipation - Dormant Projects, H2 2018
Constipation - Discontinued Products, H2 2018

List Of Figures

List of Figures
Number of Products under Development for Constipation, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Constipation - Pipeline Review, H2 2018

Constipation - Pipeline Review, H2 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Constipation - Pipeline Review, H2 2018, provides an overview of the Constipation (Gastrointestinal) pipeline landscape.Constipation

USD 2000View Report

Global Irritable Bowel Syndrome With Constipation Drugs Industry Market Research Report

The Irritable Bowel Syndrome With Constipation Drugs market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023,

USD 2960View Report

Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) - Pipeline Review, H2 2018

Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or

USD 3500View Report

Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Pipeline Review, H2 2018

Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Pipeline Review,

USD 3500View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

Discount on PDF and Enterprise Wide Licence reports
  • PDF USD 2000    USD 1600
  • Site Licence USD 4000    USD 3200
  • Enterprise Wide Licence USD 6000    USD 4800
$ 1600

Reports Details

Published Date : Jul 2018
No. of Pages :103
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube